Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267096 · ClinicalTrials.gov registry record · Phase 3
Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening
A Phase 3 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
NCT02267096 is a Phase 3 study that has completed, run by Georgetown University. The registered enrollment target is 95 participants.
The verdict
NCT02267096, a Phase 3 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
Study Summary
In 2011, the National Lung Screening Trial (NLST) reported that lung cancer mortality was reduced by 20% with spiral computed tomography (CT) compared to chest X-ray. It is estimated that 8 million people in the US are at high risk for lung cancer and that lung screening could prevent 12,000 deaths annually. Cost effectiveness models suggest that concurrent smoking cessation programs will be essential in order to realize the full benefit of screening. However, there are no clinical guidelines or evidence-based cessation protocols with demonstrated effectiveness in this setting. The investigators are addressing this gap by rigorously testing whether two scalable and pragmatic interventions can significantly boost intention to quit and cessation rates.
Interventions
- BEHAVIORAL Telephone Counseling
- BEHAVIORAL Minimal Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267096
The ClinicalTrials.gov registry entry for NCT02267096 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telephone Counseling is the first listed.
NCT02267096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02267096 about?
NCT02267096 is a clinical study titled "Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening". In 2011, the National Lung Screening Trial (NLST) reported that lung cancer mortality was reduced by 20% with spiral computed tomography (CT) compared to chest X-ray. It is estimated that 8 million people in the US are at high risk for lung cancer and that lung screening could prevent 12,000 deaths ...
What is the current status of trial NCT02267096?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2014-01. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02267096?
The interventions under investigation include: Telephone Counseling (BEHAVIORAL), Minimal Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02267096?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.